PUBLISHER: The Business Research Company | PRODUCT CODE: 1945371
PUBLISHER: The Business Research Company | PRODUCT CODE: 1945371
Infectious disease in vitro diagnostics are laboratory tests performed on samples such as blood, urine, or swabs to detect, identify, and monitor infectious pathogens including bacteria, viruses, fungi, and parasites. These diagnostics enable accurate and timely diagnosis, guide treatment decisions, and support disease surveillance and infection control.
The main product types in infectious disease in vitro diagnostics are instruments, reagents, and software and services. Instruments are tools or devices used to measure and monitor environmental conditions including air, water, soil, and noise. They utilize technologies such as molecular diagnostics, immunoassay, microbiology, hematology, urinalysis, and others. Applications include methicillin-resistant Staphylococcus aureus, Clostridium difficile, respiratory viruses, tuberculosis and drug-resistant tuberculosis, gonorrhea, human papillomavirus, human immunodeficiency virus, hepatitis C, hepatitis B, and more. End-users include hospitals, clinics, diagnostic laboratories, academic research institutes, and other organizations.
Tariffs have influenced the infectious disease IVD market by raising costs for reagents, diagnostic instruments, and laboratory consumables imported from Asia-Pacific and Europe. Molecular diagnostics and reagent segments are most affected, particularly in North America. While tariffs have created pricing challenges for laboratories, they are also driving regional manufacturing investments and strengthening domestic diagnostic supply chains.
The infectious disease in vitro diagnostics market research report is one of a series of new reports from The Business Research Company that provides infectious disease in vitro diagnostics market statistics, including infectious disease in vitro diagnostics industry global market size, regional shares, competitors with a infectious disease in vitro diagnostics market share, detailed infectious disease in vitro diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the infectious disease in vitro diagnostics industry. This infectious disease in vitro diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The infectious disease in vitro diagnostics market size has grown strongly in recent years. It will grow from $15.1 billion in 2025 to $16.13 billion in 2026 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to global infectious disease burden, hospital laboratory expansion, demand for early diagnosis, advances in immunoassays, government disease control programs.
The infectious disease in vitro diagnostics market size is expected to see strong growth in the next few years. It will grow to $21.25 billion in 2030 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to pandemic preparedness initiatives, growth in molecular diagnostics, rising antimicrobial resistance, expansion of diagnostic labs, increased healthcare screening. Major trends in the forecast period include rapid molecular diagnostic adoption, point of care infectious testing, high sensitivity pathogen detection, multiplex diagnostic panels, increased surveillance testing.
The rise in global infectious diseases drove the growth of the infectious disease in vitro diagnostics market during the historic period. Infectious diseases encompass bacterial, viral, fungal, or parasitic infections affecting populations worldwide at a given time, reflecting the overall disease burden. Changes in climate have expanded the habitats of vectors such as mosquitoes, increasing the global prevalence of infectious diseases. Infectious disease in vitro diagnostics support this trend by offering precise and timely diagnostic tools that allow healthcare providers to detect pathogens, initiate appropriate treatment, and control outbreaks efficiently. For example, in October 2024, the World Health Organization reported that approximately 10.8 million people worldwide contracted tuberculosis, with 55 percent men, 33 percent women, 12 percent children and adolescents, and 6.1 percent of cases among individuals living with HIV. Therefore, the rising global prevalence of infectious diseases contributed to the growth of the infectious disease in vitro diagnostics market during the historic period.
Major companies in the infectious disease in vitro diagnostics market are developing innovative products such as rapid detection of multiple gastrointestinal pathogens to enable timely diagnosis, improve patient outcomes, and expand point-of-care testing. Rapid detection of multiple gastrointestinal pathogens involves diagnostic tests that quickly identify several disease-causing microorganisms in the gastrointestinal tract from a single sample. In June 2024, MP Biomedicals, a US-based provider of products, chemicals, and diagnostics, launched immunochromatographic rapid diagnostic kits for gastrointestinal infectious diseases. These kits allow fast and accurate detection of Helicobacter pylori, Salmonella typhi, and Vibrio cholerae serogroups O1 and O139. They support rapid, point-of-care qualitative detection, versatile sample use including stool, blood, plasma, serum, water, and food, and are suitable for both clinical and research settings. Using immunochromatographic technology, they support early diagnosis, treatment monitoring, and confirmation of pathogen eradication, offering a combination of speed, precision, and broad pathogen coverage.
In January 2025, Fremman Capital, a UK-based private equity firm focused on healthcare and life sciences investments, acquired a majority stake in DIESSE Diagnostica Senese for an undisclosed sum. Fremman Capital intends to accelerate DIESSE's international growth and reinforce its position in the specialty in vitro diagnostics market by supporting innovation, expanding the product range for autoimmune and infectious disease diagnostics, and increasing production capacity at DIESSE's biotech campus, driving long-term sustainable growth. DIESSE Diagnostica Senese is an Italy-based developer of innovative in vitro diagnostics and reagents for autoimmunity, infectious diseases, and hematological testing, serving clinical laboratories worldwide.
Major companies operating in the infectious disease in vitro diagnostics market are F. Hoffmann-La Roche AG, Abbott Laboratories, Danaher Corporation, Thermo Fisher Scientific Inc., Siemens Healthcare AG, bioMerieux SA, QIAGEN N.V., Becton Dickinson and Company, Hologic Inc., DiaSorin S.p.A., Meridian Bioscience, Quidel Corporation, Revvity Inc., OraSure Technologies Inc., Transasia Bio-Medicals Ltd., Randox Laboratories, Luminex Corporation, Wako Pure Chemical Industries Ltd., Bio-Rad Laboratories Inc., Trivitron Healthcare
North America was the largest region in the infectious disease in vitro diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the infectious disease in vitro diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the infectious disease in vitro diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The infectious disease in vitro diagnostics market consists of revenues earned by entities by providing services such as serology testing, rapid diagnostic testing, disease surveillance and monitoring, sample collection and processing, and consulting and training services. The market value includes the value of related goods sold by the service provider or included within the service offering. The infectious disease in vitro diagnostics market also includes sales of rapid test kits, culture media, controls and calibrators, molecular sequencing kits, flow cytometry reagents, and point-of-care diagnostic devices. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Infectious Disease In Vitro Diagnostics Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses infectious disease in vitro diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for infectious disease in vitro diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The infectious disease in vitro diagnostics market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.